ELV
Elevance HealthNYSEHealth CareHealthcare PlansSnapshot 2026-05-08
As of May 8, 2026, ELV has a composite score of 27.4 and a signal label of "mild favorable." The score reflects high confidence at 80.2 and is influenced by various factors, including a macro score of 31.5 and a sector score of 7.6. The analysis is provisional, indicating that the data may be subject to change.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.07
- Bonus0.00
Why this rank
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $6.60 → $6.20 (-6.1% / 30d). 9 raised, 9 cut, 19 covering analysts.
1 upgrade, 0 downgrades / 30d, 7 maintained. 64% of analysts rate Buy.
5 PT revisions / 30d. Avg target 12.0% above current price.
1 positive, 0 negative / 30d. See F4 management tile for the event list.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
10 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Raise FY 2026 adjusted diluted EPS guidancegrowthmixed65% progress
4/22: “FY 2026 adjusted diluted EPS guidance raised to at least $26.75, supported by underlying business strength.”
Why this status
Stated in 3 of last 3 quarters. FY 2026 adjusted diluted EPS guidance was raised to at least $26.75, reflecting underlying business strength. Despite the increase in guidance, net income decreased from $2,184 million in 2025-Q1 to $1,760 million in 2026-Q1, indicating limited progress in achieving the higher EPS target.
- 2.Reaffirm FY 2026 operating cash flow guidancecapital allocationmixed65% progress
4/22: “Reaffirm FY 2026 operating cash flow of at least $5.5 billion, inclusive of potential cash payments for the CMS matter.”
Why this status
Newly stated in 2026-Q1. Operating cash flow for 2026-Q1 was $4.3 billion, reflecting a significant increase from the negative cash flow of $3.447 billion in 2025-Q4. The company is on track to meet its FY 2026 guidance of at least $5.5 billion, indicating delivering progress.
- 3.Share repurchase programcapital allocationbehind30% progress
4/22: “The Company repurchased 3.7 million shares for $1.1 billion, with $5.6 billion of authorization remaining.”
Why this status
Stated in 4 of last 4 quarters. The company repurchased 3.7 million shares for $1.1 billion in 2026-Q1, with $5.6 billion of authorization remaining. This consistent focus on share repurchase indicates a strong capital allocation strategy, delivering on its commitment to return capital to shareholders.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 28%; 252d 41%.
Drawdown — Max 1y −34%. Bad day move −3%.
Beta to sector ETF (XLV) — 1.24 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 31/100, drawdown 32/100, beta 76/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Raise FY 2026 adjusted diluted EPS guidance
GrowthElevance Health raised its full-year 2026 adjusted diluted EPS guidance to at least $26.75.
MixedStated in 3 of last 3 quarters. FY 2026 adjusted diluted EPS guidance was raised to at least $26.75, reflecting underlying business strength. Despite the increase in guidance, net income decreased from $2,184 million in 2025-Q1 to $1,760 million in 2026-Q1, indicating limited progress in achieving the higher EPS target.
FY 2026 adjusted diluted EPS guidance raised to at least $26.7565%CEO/CFO:“FY 2026 adjusted diluted EPS guidance raised to at least $26.75, supported by underlying business strength.”Press releaseSource dated 2026-04-22Stated 3 of last 8 quartersFirst seen 2026-04-22Show history (3)
- 2026-Q1Press release
“FY 2026 adjusted diluted EPS guidance raised to at least $26.75.”
- 2026-Q1Press release
“Projected FY 2026 adjusted diluted EPS to be at least $25.50.”
- 2026-Q1Press release
“Company officers will reaffirm adjusted shareholders’ earnings for full year 2026 to be at least $25.50.”
- #2
Reaffirm FY 2026 operating cash flow guidance
Capital allocationElevance Health reaffirmed its FY 2026 operating cash flow guidance of at least $5.5 billion.
MixedNewly stated in 2026-Q1. Operating cash flow for 2026-Q1 was $4.3 billion, reflecting a significant increase from the negative cash flow of $3.447 billion in 2025-Q4. The company is on track to meet its FY 2026 guidance of at least $5.5 billion, indicating delivering progress.
Operating cash flow of $4.3 billion in 2026-Q165%CEO/CFO:“Reaffirm FY 2026 operating cash flow of at least $5.5 billion, inclusive of potential cash payments for the CMS matter.”Press releaseSource dated 2026-04-22Stated 1 of last 8 quartersFirst seen 2026-04-22Show history (1)
- 2026-Q1Press release
“Reaffirm FY 2026 operating cash flow of at least $5.5 billion.”
- #3
Share repurchase program
Capital allocationElevance Health announced a share repurchase program with $5.6 billion remaining authorization.
BehindStated in 4 of last 4 quarters. The company repurchased 3.7 million shares for $1.1 billion in 2026-Q1, with $5.6 billion of authorization remaining. This consistent focus on share repurchase indicates a strong capital allocation strategy, delivering on its commitment to return capital to shareholders.
Repurchased 3.7 million shares for $1.1 billion30%CEO/CFO:“The Company repurchased 3.7 million shares for $1.1 billion, with $5.6 billion of authorization remaining.”Press releaseSource dated 2026-04-22Stated 4 of last 8 quartersFirst seen 2026-04-22Show history (4)
- 2026-Q1Press release
“Repurchased 3.7 million shares for $1.1 billion.”
- 2025-Q4Press release
“Share buyback announced.”
- 2025-Q3Press release
“Share buyback announced.”
- 2025-Q2Press release
“Share buyback announced.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
ELV Elevance Health | +27 | inexpensive | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-04-22)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-04-22)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-2216d agoItem 2.02
or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.
earnings preannouncementpositivescore 50 - 2026-03-101mo agoItem 7.01
Regulation FD Disclosure Officers of Elevance Health, Inc. (the “Company”) expect to speak with investors and analysts over the next week. During these meetings, Company officers will reaffirm adjusted shareholders’ earnings for full year 2026 to be at least $25.50 per diluted share. The Company also will reaffirm its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. As reported in a Current Report on Form 8-K filed by the Company on March 2, 2026, the Company was no…
capital allocationpositivescore 13 - 2026-02-262mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 26, 2026, Elevance Health, Inc. (the “Company”) announced certain management changes. Among these changes, Peter D. Haytaian will transition from his role as Executive Vice President and President of Carelon, effective May 4, 2026, to devote more time to family commitments. Mr. Haytaian will serve the Company as Special Advisor through…
executive changeneutralscore 11 - 2026-03-022mo agoItem 8.01
Regulation FD Disclosure On February 27, 2026, Elevance Health, Inc. (the “Company”) was notified by the Centers for Medicare & Medicaid Services (“CMS”) of its intent to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into the Company’s Medicare Advantage-Prescription Drug (“MA-PD”) plans and suspending certain communication activities to Medicare beneficiaries. The sanctions are scheduled to take effect on March 31, 2026 unless CMS determines that the issues id…
capital allocationpositivescore 11 - 2026-02-262mo agoItem 7.01
hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings. FORWARD-LOOKING STATEMENTS This document contains certai…
capital allocationpositivescore 10
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.